The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis

Journal of Clinical and Experimental Hepatology

Volumn 5, Issue 2, 2015, Pages 147-158

  Sharma, Mithun ^a   Mitnala, Shasikala ^a   Vishnubhotla, Ravi K ^a   Mukherjee, Rathin ^a   Reddy, Duvvur N ^a   Rao, Padaki N ^a  

^a ASIAN INSTITUTE OF GASTROENTEROLOGY   (India)

Author keywords

Adiponectin; Cytokines; Gut microbiota; Lipotoxicity; PNPLA3

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN C3; CYTOKINE; FRUCTOSE; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; POLYUNSATURATED FATTY ACID;

AMINO ACID SUBSTITUTION; APOC3 GENE; CYTOKINE PRODUCTION; DISEASE COURSE; FOOD INTAKE; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; INSULIN RESISTANCE; INTESTINE FLORA; LIPOTOXICITY; LIVER CIRRHOSIS; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PNPLA3 GENE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84952874326     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2015.02.002     Document Type: Review

References (150)

1. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guidelines by the American Association for the study of Liver diseases, American College of Gastroenterology, and the American Gastroenterological Association. Gastroenterology 2012, 142:1592-1609.
2. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
3. Bellentani S., Saccoccio G., Masutt F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132:112-117.
4. Luyckx F.H., Desaive C., Thiry A., et al. Liver abnormalities in severely obese subjects. Effect of drastic weight loss after gastroplasty. Int J Obes 1998, 22:222-226.
5. Chiloiro M., Caruso M.G., Cisternino A.M., et al. Ultrasound evaluation and correlates of fatty liver disease: a population study in a Mediterranean area. Metab Syndr Relat Disord 2013, 11:349-358.
6. Fan J.G. Epidemiology of alcoholic and non-alcoholic fatty liver disease in china. J Gastroenterol Hepatol 2013, 28(suppl 1):11-17.
7. Lankarani K.B., Ghaffarpasand F., Mahmoodi M., et al. Non alcoholic fatty liver disease in Southern Iran: a population based study. Hepat Mon 2013, 13:e9248.
8. Eguchi Y., Hyogo H., Ono M., et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a muticentre large retrospective study. J Gastroenterol 2012, 47:586-595.
9. Loomba R., Abraham M., Unalp A., et al. Association between diabetes, family history of diabetes and risk factors of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012, 56:943-951.
10. Farrell G.C., Wong V.W., Chitturi S. NAFLD in Asia - as common and important as in West. Nat Rev Gastroenterol Hepatol 2013, 10:307-318.
11. Das K., Das K., Mukherjee P.S., et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010, 51:1593-1602.
12. Amarapurkar D., Kamani P., Patel N., et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol 2007, 6:161-163.
13. Singh S.P., Nayak S., Swain M., et al. Prevalence of nonalcoholic fatty liver disease in costal eastern India: a preliminary ultrasonographic survey. Trop Gastroenterol 2004, 25:76-79.
14. Fan J.G., Li F., Cai X.B., Peng Y.D., Ao Q.H., Gao Y. Effects of nonalcoholic fatty liver disease on development of metabolic disorders. J Gastroenterol Hepatol 2007, 22:1086-1091.
15. Petersen K.F., Dufour S., Feng J., et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian men. Proc Natl Acad Sci U S A 2006, 103:18273-18277.
16. Dasarathy S., Dasarathy J., Khiyami A., Joseph R., Lopez R., Mc Cullough A.J. Validity of realtime ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009, 51:1061-1067.
17. Sczepaniak L.S., Nurenberg P., Leonard D.S., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in general population. Am J Physiol Endocrinol Metab 2005, 288:E462-E468.
18. Mofrad P., Contos M.J., Haque M., et al. Clinical and histological spectrum of non-alcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37:1286-1292.
19. Yilmaz Y., Eren F. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2014, 26:1292-1295.
20. Duseja A., Das A., Das R., et al. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig Dis Sci 2007, 52:2368-2374.
21. Singh S.P., Kar S.K., Panigrahi M.K., et al. Profile of patients with incidentally detected nonalcoholic fatty liver disease (IDNAFLD) in costal eastern India. Trop Gastroenterol 2013, 34:144-152.
22. Wong V.W., Wong G.L., Choi P.C., et al. Disease progression of nonalcoholic fatty liver disease: a prospective study with paired liver biopsy at 3 years. Gut 2010, 59:969-974.
23. Mc Pherson S., Hardy T., Henderson E., Burt A.D., Day C.P., Anstee Q.M. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implication for prognosis and clinical management. J Hepatol 2014, 29. S0168-8278(14)00883-6.
24. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
25. Musso G., Gambino R., Cassader M., Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011, 43:617-649.
26. Day C.P., James O.F. Steatohepatitis: a tale of two"hits"?. Gastroenterology 1998, 114:842-845.
27. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hit hypothesis. Hepatology 2010, 52:1836-1846.
28. Wree A., Broderick Lori, Canbay All, Hoffmann Hal M., Feldstein Ariel E. From NAFLD to NASH to cirrhosis - new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013, 10:627-636.
29. Schwimmer J.B., Celedon M.A., Lavine J.E., et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009, 136:1585-1592.
30. Speliotes E.K., Yerges-Armstrong L.M., Wu J., et al. Genome- wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011, 7:e1001324.
31. Kawaguchi T., Sumida Y., Umemura A., et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 2012, 7:e38322.
32. Chalasani N., Guo X., Loomba R., et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010, 139:1567-1576.
33. He S., McPhaul C., Li J.Z., et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010, 285:6706-6715.
34. Rotman Y., Koh C., Zmuda J.M., Kleiner D.E., Liang T.J. The association of genetic variability in palatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010, 50:894-903.
35. Bhatt S.P., Nigam P., Misra A., Guleria R., Pandey R.M., Pasha M.A. Genetic variation in the patatin-like phospholipase domain-containing protein-3 (PNPLA-3) gene in Asian Indians with nonalcoholic fatty liver disease. Metab Syndr Relat Disord 2013, 11:329-335.
36. Liu Y.L., Patman G.L., Leathart J.B.S., et al. Carriage of PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated with hepatocellular carcinoma. J Hepatol 2014, 61:75-81.
37. Stefano R., Julia K., Chao X., et al. Genetic variation in PNPLA3 confers susceptibility to non-alcoholic fatty liver disease. Nat Genet 2008, 40:1461-1465.
38. Onuma H., Tabara Y., Kawamoto R., et al. The GCKR rs780094 polymorphism is associated with susceptibility of type 2 diabetes, reduced fasting plasma glucose levels, increased triglycerides levels and lower HOMA-IR in Japanese population. J Hum Genet 2010, 55:600-604.
39. Kanth V.V., Sasikala M., Rao P.N., et al. Pooled genetic analysis in ultrasound measured non-alcoholic fatty liver disease in Indian subjects: a pilot study. World J Hepatol 2014, 6:435-442.
40. Sun S., Wang M., Song H., et al. SCAP gene polymorphisms decrease the risk of nonalcoholic fatty liver disease in females with metabolic syndrome. J Genet 2013, 92:565-570.
41. Zain S.M., Mohamed Z., Mahadeva S., et al. Susceptibility and gene interaction study of the angiotensin II type 1 receptor (AGTR1) gene polymorphisms with non-alcoholic fatty liver disease in a multi-ethnic population. PLoS One 2013, 8:e58538.
42. Chen S., Li Y., Li S., Yu C.A. Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio. J Gastroenterol Hepatol 2008, 23:1415-1418.
43. Xu Y.P., Liang L., Wang C.L., et al. Association between UCP3 gene polymorphisms and nonalcoholic fatty liver disease in Chinese children. World J Gastroenterol 2013, 19:5897-5903.
44. Musso G., Bo S., Cassader M., DeMichieli F., Gambino R. Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism. Am J Clin Nutr 2013, 98:895-906.
45. Barbieri M., Esposito A., Angellotti E., Rizzo M.R., Marfella R., Paolisso G. Association of genetic variation in adaptor protein APPL1/APPL2 loci with non-alcoholic fatty liver disease. PLoS One 2013, 8:e71391.
46. Sazci A., Ozel M.D., Ergul E., Aygun C. Association of nicotinamide-N-methyltransferase gene rs694539 variant with patients with nonalcoholic steatohepatitis. Genet Test Mol Biomarkers 2013, 17:849-853.
47. Namikawa C., Shu-Ping Z., Vyselaar J.R., et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 2004, 40:781-786.
48. Peterson K.F., Dufour S., Hariri A., et al. Apolipoprotein C3 gene variants in non-alcoholic fatty liver disease. N Eng J Med 2010, 362:1082-1089.
49. Puppala J, Bhrugumalla S, Kumar A, et al Apolipoprotein C3 gene polymorphism in Southern Indian patients with nonalcoholic fatty liver disease. Indian J Gastroenterol [epub] 2014.Oct 17.
50. Ravikanth V.V., Sasikala M., Urmila S.A. PNPLA3 gene polymorphism but not APOC3 enhances risk for nonalcoholic fatty liver disease in Indian subjects. J Clin Exp Hepatol 2013, 3:S24.
51. Santoro N., Savoye M., Kim G., et al. Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake. PLoS One 2012, 7:e37827.
52. Sevastianova K., Kotronen A., Gastaldelli A., et al. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr 2011, 94:104-111.
53. Stickel F., Buch S., Lau K., et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in Caucasians. Hepatology 2011, 53:86-95.
54. Dhillon B.K., Das R., Garewal G., et al. Frequency of primary iron overload and HFE gene mutations (C282Y, H63D and S65C0 in chronic liver disease patients in North India. World J Gastroenterol 2007, 13:2956-2959.
55. Das U.N. Biological significance of essential fatty acids. J Assoc Physicians India 2006 Apr, 54:309-319.
56. Seki H., Tani Y., Arita M. Omega-3 PUFA derived anti-inflammatory lipid mediator resolving E1. Prostaglandins Other Lipid Mediat 2009, 89:126-130.
57. Dentin R., Benhamed F., Pégorier J.P., et al. Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through inhibition of ChREBP nuclear protein translocation. J Clin Invest 2005, 15:2843-2854.
58. Araya J., Rodrigo R., Videla L.A., et al. Increase in long chain polyunsaturated fatty acid n6/n3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004, 106:635-643.
59. Parker H.M., Johnson N.A., Burdon C.A., Cohn J.S., O'Connor H.T., George J. Omega 3 supplementation and non alcoholic fatty liver disease: a systemic review and meta-analysis. J Hepatol 2012, 56:944-951.
60. Feldstein A.E., Lopez R., Tamimi T.A., et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res 2010, 51:3046-3054.
61. Monetti M., Levin M.C., Watt M.J., et al. Dissociation of hepatic steatosis and insulin resistance in mice over expressing DGAT in the liver. Cell Metab 2007, 6:69-78.
62. Liao W., Hui T.Y., Young S.G., Davis R.A. Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER. J Lipid Res 2003, 44:978-985.
63. Li Z.Z., Berk M., McIntyre T.M., Feldstein A.E. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem 2009 Feb 27, 284:5637-5644.
64. Ntambi J.M., Miyazaki M., Stoehr J.P., et al. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci U S A 2002, 99:11482-11486.
65. Neuschwander-Tetri B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52:774-788.
66. Scorletti E., Bhatia L., McCormick K.G., et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: results from the *WELCOME study. Hepatology 2014, 60:1211-1221.
67. Han M.S., Park S.Y., Shinzawa K., et al. Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes. J Lipid Res 2008, 49:84-97.
68. Sinn D.H., Gwak G.Y., Park H.N., et al. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. Am J Gastroenterol 2012, 107:561-567.
69. Kumar R., Rastogi A., Sharma M.K., et al. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: do they differ from obese or overweight non-alcoholic fatty liver disease?. Indian J Endocrinol Metab 2013, 17:665-671.
70. Choudhary N.S., Duseja A., Kalra N., Das A., Dhiman R.K., Chawla Y.K. Correlation of adipose tissue with liver histology in Asian Indian patients with nonalcoholic fatty liver disease (NAFLD). Ann Hepatol 2012, 11:478-486.
71. Sanal M.G., Sarin S.K. Association of nonalcoholic fatty liver disease with metabolic syndrome in Indian population. Diabetes Metab Syndr 2011, 5:76-80.
72. Bajaj S., Nigam P., Luthra A., et al. A case control study on insulin resistance, metabolic co-variates and prediction score in non-alcoholic fatty liver disease. Indian J Med Res 2009, 129:285-292.
73. Singh S.P., Misra B., Kar S.K., et al. Nonalcoholic fatty liver disease (NAFLD) without insulin resistance: Is it different?. Clin Res Hepatol Gastroenterol 2014 Dec 17, pii: S2210-7401(14)00285-X. http://dx.doi.org/10.1016/j.clinre.2014.08.014. [epub ahead of print].
74. Bhat G., Baba C.S., Pandey A., Kumari N., Choudhuri G. Insulin resistance and metabolic syndrome in nonobese Indian patients with nonalcoholic fatty liver disease. Trop Gastroenterol 2013, 34:18-24.
75. Stanhope K.L., Havel P.J. Fructose consumption: recent results and their potential implications. Ann N Y Acad Sci 2010, 1190:15-24.
76. Lustig R.H. Fructose: metabolic, hedonic, and societal parallels with ethanol. J Am Diet Assoc 2010, 110:1307-1321.
77. Lim J.S., Mietus-Snyder M., Valente A., Schwarz J.M., Lustig R.H. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 2010, 7:251-264.
78. Lê K.A., Tappy L. Metabolic effects of fructose. Curr Opin Clin Nutr Metab Care 2006, 9:469-475.
79. D'Angelo G., Elmarakby A.A., Pollock D.M., Stepp D.W. Fructose feeding increases insulin resistance but not blood pressure in Sprague-Dawley rats. Hypertension 2005 Oct, 46:806-811.
80. Nolan J.P. The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 2010, 52:1829-1835.
81. Aigner E., Strasser M., Haufe H., et al. A role for low hepatic copper concentrations in nonalcoholic fatty liver disease. Am J Gastroenterol 2010, 105:1978-1985.
82. Nelson J.E., Klintworth H., Kowdley K.V. Iron metabolism in nonalcoholic fatty liver disease. Curr Gastroenterol Rep 2012, 14:8-16.
83. Ibrahim M.M. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 2010, 11:11-18.
84. Rodríguez A., Catalán V., Gómez- Ambrosi J., Frühbeck G. Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome?. Curr Pharm Des 2007, 13:2169-2175.
85. Leung C., Herath C.B., Jia Z., et al. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J Hepatol 2014, 60:832-838.
86. Mastrocola R., Collino M., Rogazzo M., et al. Advanced glycation end products promote hepatosteatosis by interfering with SCAP-SREBP pathway in fructose-drinking mice. Am J Physiol Gastrointest Liver Physiol 2013, 305:G398-G407.
87. Tang X.Z., Jo J., Tan A.T., et al. IL-7 licenses activation of human liver intra sinusoidal mucosal-associated invariant T cells. J Immunol 2013, 190:3142-3152.
88. Longhi M.S., Ma Y., Mieli-Vergani G., Vergani D. Regulatory T cells in autoimmune hepatitis. J Hepatol 2012, 57:932-933.
89. Lleo A., Invernizzi P. Apotopes and innate immune system: novel players in the primary biliary cirrhosis scenario. Dig Liver Dis 2013, 45:630-636.
90. Rana D., Duseja A., Dhiman R.K., Chawla Y., Arora S.K. Maturation defective myeloid dendritic cells in nonalcoholic fatty liver disease patients release inflammatory cytokines in response to endotoxin. Hepatol Int 2013, 7:562-569.
91. Schulz C., Gomez P.E., Chorro L., et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012, 336:86-90.
92. Tang T., Sui Y., Lian M., Li Z., Hua J. Pro-inflammatory activated kupffer cells by lipids induce hepatic NKT cells deficiency through activation-induced cell death. PLoS One 2013, 8:e81949.
93. Knolle P., Schlaak J., Uhrig A., Kempf P., Meyerzum Buschenfelde K.H., Gerken G. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide(LPS) challenge. J Hepatol 1995, 22:226-229.
94. Seki E., Tsutsui H., Nakano H., et al. Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor88 that is critically involved in induction of production of IL-12and IL-1b. J Immunol 2001, 166:2651-2657.
95. Gatselis N.K., Ntaios G., Makaritsis K., Dalekos G.N. Adiponectin: a key play-maker adipocytokine in non-alcoholic fatty liver disease. Clin Exp Med 2014, 14:121-131.
96. Han M.S., Jung D.Y., More I.C., et al. JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science 2013;11, 339:218-222.
97. Liu Y., Chen K., Wang C., et al. Cell surface receptor FPR2 promotes antitumor host defense by limiting M2 polarization of macrophages. Cancer Res 2013, 73:550-560.
98. Zhan Y.T., An W. Roles of liver innate immune cells in nonalcoholic fatty liver disease. World J Gastroenterol 2010, 16:4652-4660.
99. O'Shea D., Cawood T.J., O'Farrelly C., Lynch L. Natural killer cells in obesity: impaired function and increased susceptibility to the effects of cigarette smoke. PLoS One 2010, 5:e8660.
100. Kahraman A., Schlattjan M., Kocabayoglu P., et al. Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. Hepatology 2010, 51:92-102.
101. Bendelac A., Savage P.B., Teyton L. The biology of NKT cells. Annu Rev Immunol 2007, 25:297-336.
102. Park O., Jeong W.I., Wang L., et al. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 2009, 49:1683-1694.
103. Syn W.K., Oo Y.H., Pereira T.A., et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 2010, 51:1998-2007.
104. Liu S., Gallo D.J., Green A.M., et al. Role of toll-like receptors in changes in gene expression and NF-kappa B activation in mouse hepatocytes stimulated with lipopolysaccharide. Infect Immun 2002, 70:3433-3442.
105. Matsumura T., Degawa T., Takii T., et al. TRAF6-NF-kappaB pathway is essential for interleukin-1-induced TLR2 expression and its functional response to TLR2 ligand in murine hepatocytes. Immunology 2003, 109:127-136.
106. Mimura Y., Sakisaka S., Harada M., Sata M., Tanikawa K. Role of hepatocytes in direct clearance of lipopolysaccharide in rats. Gastroenterology 1995, 109:1969-1976.
107. Li L., Chen L., Hu L., et al. Nuclear factor high-mobility group box1 mediating the activation of toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 2011, 54:1620-1630.
108. Fujii H., Kawada N. Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol 2012, 47:215-225.
109. Tsukamoto H., She H., Hazra S., Cheng J., Miyahara T. Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation. J Gastroenterol Hepatol 2006, (suppl 3):S102-S105. [abstract].
110. Choi S.S., Witek R.P., Yang L., et al. Activation of Rac1 promotes hedgehog-mediated acquisition of the myofibroblastic phenotype in rat and human hepatic stellate cells. Hepatology 2010, 52:278-290.
111. De Minicis S., Svegliati-Baroni G. Fibrogenesis in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011, 5:179-187.
112. Choi S.S., Syn W.K., Karaca G.F., et al. Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J Biol Chem 2010; 19, 285:36551-36560.
113. Ikejima K., Takei Y., Honda H., et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002, 122:1399-1410.
114. Seki E., Brenner D.A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008, 48:322-335.
115. Ikeda H., Sasaki M., Ishikawa A., et al. Interaction of Toll-like receptors with bacterial components induces expression of CDX2 and MUC2 in rat biliary epithelium in vivo and in culture. Lab Invest 2007, 87:559-571.
116. Harada K., Isse K., Nakanuma Y. Interferon gamma accelerates NF-kappaB activation of biliary epithelial cells induced by Toll-like receptor and ligand interaction. J Clin Pathol 2006, 59:184-190.
117. Chiba M., Sasaki M., Kitamura S., Ikeda H., Sato Y., Nakanuma Y. Participation of bile ductular cells in the pathological progression of non-alcoholic fatty liver disease. J Clin Pathol 2011, 64:564-570.
118. Tilg H., Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 16, 343:1467-1476.
119. Jarrar M.H., Baranova A., Collantes R., et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008, 27:412-421.
120. Crespo J., Cayon A., Fernandez-Gil P., et al. Gene expression of tumor necrosis factor alpha and TNF-receptors,p55 and p75,in nonalcoholic steatohepatitis patients. Hepatology 2001, 34:1158-1163.
121. Manco M., Marcellini M., Giannone G., Nobili V. Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol 2007, 127:954-960.
122. Tokushige K., Takakura M., Tsuchiya-Matsushita N., Taniai M., Hashimoto E., Shiratori K. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol 2007, 46:1104-1110. PMID:17395331. 10.1016/j.jhep.2007.01.028.
123. Sabio G., Das M., Mora A., et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008, 322:1539-1543.
124. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
125. Kumar R., Prakash S., Chhabra S., et al. Association of pro-inflammatory cytokines, adipokines and oxidative stress with insulin resistance and non-alcoholic fatty liver disease. Indian J Med Res 2012, 136:229-236.
126. Kumar A., Sharma A., Duseja A., et al. Patients with nonalcoholic fatty liver disease (NAFLD) have higher oxidative stress in comparison to chronic viral hepatitis. J Clin Exp Hepatol 2013, 3:12-18.
127. Narasimhan S., Gokulakrishnana K., Sampathkumar R., et al. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem 2011, 40:815-821.
128. Miura K., Kodama Y., Inokuchi S., et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010, 139:323-334. e7. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 2011 Jul;54(1):133-44.
129. Csak T., Ganz M., Pepsia J., Kodys K., Dolganiuc A., Szabo G. Fatty liver and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011, 54:133-144.
130. Netea M.G., Nold-Petry C.A., Nold M.F., et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009;5, 113:2324-2335.
131. Csak T., Dolganiuc A., Kodys K., et al. Mitochondrial antiviral signaling protein defect links impaired antiviral response and liver injury in steatohepatitis in mice. Hepatology 2011, 53:1917-1931.
132. Ricchi M., Odoardi M.R., Carulli L., et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 2009, 24:830-840.
133. Ji J., Zhang L., Wang P., et al. Saturated free fatty acid, palmitic acid, induces apoptosis in fetal hepatocytes in culture. Exp Toxicol Pathol 2005, 56:369-376.
134. Tsochatzis E.A., Papatheodoridis G.V., Archimandritis A.J. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009, 2009:831670.
135. Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 10:772-783.
136. Hui J.M., Hodge A., Farrell G.C., Kench J.G., Kriketos A., George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 2004, 40:46-54.
137. Hijona E., Hijona L., Arenas J.I., Bujanda L. Inflammatory mediators of hepatic steatosis. Mediat Inflamm 2010, 2010:837419.
138. Bajaj M., Suraamornkul S., Piper P., et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004, 89:200-206.
139. Gaddipati R., Sasikala M., Padaki N., et al. Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. Ann Hepatol 2010, 9:266-270.
140. Myers M.G., Cowley M.A., Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008, 70:537-556.
141. Uygun A., Kadayifci A., Yesilova Z., et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000, 95:3584-3589.
142. Xiao D.H., Yan F., Hen Z., et al. Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. World J Gastroenterol 2008, 14:2888-2893.
143. Qin J., Li R., Raes J., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
144. Whitman W.B., Coleman D.C., Wiebe W.J. Prokaryotes: the unseen majority. Proc Natl Acad Sci U S A 1998, 95:6578-6583.
145. Mouzaki M., Comelli E.M., Arendt B.M., et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013, 58:120-127.
146. Miele L., Valenza V., La Torre G., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49:1877-1887.
147. Compare D., Coccoli P., Rocco A., et al. Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012, 22:471-476.
148. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 21, 444:1022-1023.
149. Jacob A.I., Goldberg P.K., Bloom N., Degenshein G.A., Kozinn P.J. Endotoxin and bacteria in portal blood. Gastroenterology 1977, 72:1268-1270.
150. Zhu L., Baker S.S., Gill C., et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013, 57:601-609.